Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP) announced its quarterly earnings results on Wednesday. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.01.

Shares of Titan Pharmaceuticals (OTCMKTS:TTNP) opened at 4.40 on Friday. The company has a market cap of $93.27 million and a P/E ratio of 14.86. The company’s 50-day moving average price is $5.25 and its 200-day moving average price is $5.55. Titan Pharmaceuticals has a 12 month low of $2.57 and a 12 month high of $8.74.

Earnings History for Titan Pharmaceuticals (OTCMKTS:TTNP)

Separately, TheStreet raised Titan Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 6th.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura.

Receive News & Stock Ratings for Titan Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.